摘要
目的:评价和分析血清乙肝表面抗原(HBsAg)定量检测对聚乙二醇-α2a(PegIFN-α2a)治疗HBeAg阳性患者慢性乙型肝炎(CHB)的远期疗效。方法:选取2012年1月—2015年1月间收治的HBeAg阳性CHB患者80例(其中B基因型30例和C基因型50例),均采用PegIFN-α2a治疗,每周1次,连续治疗48周,并随访24周,评价其临床疗效。结果:治疗结束后随访24周,根据血清HBV-DNA变化将患者分为病毒血持续应答组(SVR)、复发组和无应答组;治疗第12、24及48周时,持续应答组患者血清HBV-DNA水平与复发组比较其差异无统计学意义(P>0.05),血清HBsAg水平明显低于复发组(P>0.05);治疗第24周,28例患者血清HBsAg测得值降低>90%,其中25例最终达到了SVR;52例患者降低<90%,其中仅有3例患者达到了SVR(P<0.05);另外,B基因型持续应答率(13/30)高于C基因型(15/50)(P>0.05)。结论:定量检测血清HBsAg可作为预测PegIFN-α2a治疗HBeAg阳性CHB患者远期疗效的有效指标。
Objective： To explore the value of serum HBsAg quantification in prediction of interferon treatment of HBeAg-positive chronic hepatitis B（CHB）. Methods ： 80 patients（B genotype 30 and C genotype 50） with HBeAg-positire CHB received PegIFN-α2a once a week for 48 weeks, and then they were follow up for 24 weeks. Results： The patients were divided into sustained virus response （SVR） group, relapse group,and non-response group. During the treatment, serum level of HBV DNA of SVR group did not differ significantly from relapse group, and they were lower than that in non-response group. However, serum level of HBsAg quantification of SVR group was lower than that in relapse group, there was no significant difference in HBsAg quantification between relapse group and non-response group. 28 serum HBsAg declined more than 90% at weeks 24, 25 of them reached SVR;52 serum HBsAg declined less than 90%, 3 of them reached SVR, there was significant difference. SVR rate of B genotype to interferon was higher than that of C genotype, but there was no significant difference between two groups. Conclusion： Serum HBsAg quantification is an effective parameter for predicting the efficacy of interferon therapy in HBeAg-positive CHB.
出处
《抗感染药学》
2017年第4期822-825,共4页
Anti-infection Pharmacy
